#digital twin in clinical trials

[jcmarchi]

Jeff Elton, CEO at ConcertAI – Interview Series

New Post has been published on https://thedigitalinsider.com/jeff-elton-ceo-at-concertai-interview-series/

Jeff Elton, CEO at ConcertAI – Interview Series

Jeff Elton, Ph.D., is CEO of ConcertAI, an AI SaaS solutions company providing research solutions and patient-centric solutions for life sciences innovators and the world’s leading providers.  ConcertAI is focused on accelerating and improving the precision of retrospective and prospective clinical studies using provider EMRs, LISs, and PACSs systems as the source for all study data.  It is a long-term partner partner with the American Society of Clinical Oncology and its CancerLinQ program, US FDA, NCI Health Equity initiatives, and almost 100 healthcare providers across the US.

Prior to ConcertAI, Jeff was Managing Director, Accenture Strategy/Patient Health; Global Chief Operating Officer and SVP Strategy at Novartis Institutes of BioMedical Research, Inc.; and partner at McKinsey & Company.  He is also a founding board member and senior advisor to several early-stage companies. Jeff is currently a board member of the Massachusetts Biotechnology Council. He is the co-author of the widely cited book, Healthcare Disrupted (Wiley, 2016).  Jeff has a Ph.D. and M.B.A. from The University of Chicago.

As the founding CEO of ConcertAI, can you share your vision for the company at its inception? How has that vision evolved since 2018?

We started with the idea that improved patient outcomes come from deep and actionable insights. Gaining those insights requires data completeness, data scale, data representativeness and advanced AI intelligence. So, we created a Data-as-a-Service and AI Software-as-a-Service company. We targeted AI that allows inferencing and prediction. This included predicting events to avoid, such as patients’ non-adherence to their therapy or discontinuation of care because of a lack of positive response, which informed when clinical trials might be the next option.

Our vision has remained steadfast, and we continue to expect more out of our solutions. With the latest generation of LLMs, agentic AI and other generative AI solutions, we can operate at scale (and almost in real-time—something we did not expect or anticipate in 2018). With partners like NVIDIA, we can advance our solutions to perform better than expected, recognize limitations and unique characteristics, and move at the pace of the entire market’s innovations—the journey so far has been extraordinarily productive and exhilarating.

We have opened up previously unimaginable performance in clinical trial automation solutions, automating the placement of patients on evidence-based clinical pathways, advanced workflows in radiological interpretation, and the use of digital twins as a decision-enhancing tool for care and research.

Today, we serve almost 50 biopharma innovators and 2,000 healthcare providers—so while not at quite the scale of the entire market, we are the broadest-reaching AI solutions for oncology in the industry.

What inspired you to focus on oncology and hematology datasets specifically, and how did you see ConcertAI making a difference in these fields?

The United States started the “War on Cancer” in 1971 with the National Cancer Act. This catalyzed large-scale government funding, which generated insights into the mutations that drive cancers, new modalities for therapies, expanded National Cancer Institute-designated treatment centers, and more. Under the Obama administration, funding increased again by $10 billion in electronic stimulus going to the NIH and, in turn, to the NCI. Under Biden, the Cancer Moonshot 2.0 program was launched in 2022, again catalyzing an entirely new generation of research and seed funding investment for academic, community, and private-public partnerships.

I give this history because few diseases or areas of healthcare have the level of data: genomic, transcriptomic, digital pathology, digital radiology, detailed electronic medical records, etc., and the level of research that contextualizes these data with validated insights through rigorous, multi-center, peer-review studies. As further evidence, the American Society of Clinical Oncology annual meeting is the largest medical meeting in the world, with the greatest number of new publications, posters and abstracts of any scientific forum on any topic.

So, if you are going to be data and AI-centric, there are few better areas to advance solutions with confidence and at scale than oncology. ConcertAI has the largest collection of research-grade data of anyone in the world. It includes hundreds of peer-reviewed publications enabled by that data, significant evidence resulting from those publications changing how patients are treated and assuring the most positive possible outcomes, and now AI SaaS technologies that are integral to the processes of care and research that bring the power of that data and evidence to bear at all points and for all decisions along a patient’s care journey. What is really important here is that we don’t do this unilaterally. It is done transparently with our healthcare provider and biopharma innovator partners to engender the greatest confidence and use. So, we are evolving toward real-time, advanced, AI intelligence-enabled decision augmentation.

ConcertAI has become a leading player in real-world evidence (RWE) and AI technology for healthcare. What were some of the early challenges you faced in positioning the company as a leader in this space?

You have to be trusted and evolve towards being the reference source. That is earned. The trust comes from your provider partners, believing that the data you are accessing is in the best interests of their patients. Trust comes from your academic and industry partners, who see the evidence of and believe that your data is derived as a perfect reflection of the original patient records and that the concepts you advance are ��true’ and reflective of current clinical and scientific practice. You also have to achieve a scale that your data solutions represent not only the entire population but also produce conclusions that are confidently generalizable back to the full population being treated with a particular medicine. Technology is similar. Scientists and clinicians are inherently skeptical—as they should be—and don’t trust black boxes or algorithms they don’t understand. So we needed to establish trust there, too, through publications and being open about how our solutions work.

ConcertAI holds the world’s largest oncology and hematology dataset. What unique opportunities does this data create for transforming cancer research and treatment?

I love that question. We are working on this every day! The opportunities to provide value to providers, patients and innovators are almost limitless. In early-phase trials, we are evolving study simulation approaches with digital twins that will change the programs we take into clinical trials. Our data and AI optimizations will lower the time required to go from finalized protocol to finalized submission to regulators by 30 to 40%—meaning new medicines get to patients faster. Our decision augmentation AI solutions will recommend pathways for treatment that are evidence-based and specifically tailored to those pathways, monitor responses in line with the predicted response, and look for potentially beneficial clinical trials when response or benefit is below expectations. Our imaging clinical interpretation solutions operate at the level of operational processes, clinical interpretation, and longer-term view of new interpretations or new interventions that should be considered based on insights and evidence in the future. No longer is an action “once and done” but rather it becomes “once, and then again and again” such that beneficial reassessments and future decisions are an ongoing process! What’s different here is that the view is the entire patient journey—this is a horizontal view versus a series of narrow, deep, vertical views that have to be stitched together. This is an innovation enabled by AI and a profound process change that provides new ways of working to the expert humans involved.

Can you explain how ConcertAI’s Digital Trial Solution works to match cancer patients with life-saving clinical trials? What impact have you seen so far in terms of patient outcomes?

Clinical trials are very complex and require hours of effort by a wide range of highly expert individuals. For most organizations, clinical trials are offered as a responsibility and commitment to patients where the current standard of care may not represent a viable alternative. Trials have not really been very available to patients in community treatment centers, where 80% of patients receive their care. Yet, these are the patients who will ultimately be receiving newly approved medicines. This creates a double dilemma: the majority of patients who need access to trials are limited, and those who are reflective of the ultimate standard of care population are not in the trial dataset. We set a path to resolve these problems.

The results have been great—so positive that we are going to be expanding our number of studies underway by 10x in 2025. We published this for the last American Society of Clinical Oncology meetings and in other areas. Our approach is how we think AI should be implemented—as an augmentation of expert humans where there are large capacity and talent constraints and where lives are at stake. We have developed a set of orchestrated and tuned large language models that access patient records, synthesize characteristics, and match patients to potentially beneficial trials, doing exactly what the expert humans would do—with a fully documented approach to making recommendations and assessments. In the sites where our technologies are deployed, we perform at the level of the most expert humans and accrue patients at 5x or more relative to sites where our technologies are not deployed—the research teams and biopharma innovators are both pleased, and patients benefit most.

How does ConcertAI’s AI-driven approach to trial design and patient recruitment address some of the current limitations in clinical research, such as patient diversity and trial efficiency?

I am proud of my team—they told me three to four years ago that achieving diversity is an obligation and the right thing to do scientifically. They also maintained that it is hard to do if it is manual but requires zero incremental effort if automated. So, we decided then that every dataset and AI SaaS solution would integrate diversity and social determinants of health characteristics as our standard approach. It’s not an option. It’s just what we do. Subsequently, our CARAai™ supported clinical trial design and optimization solutions can assess what ethnic, racial or economic subpopulations may be most adversely impacted by a disease, integrate those considerations into the trial design, ensure that these populations are not unwittingly excluded, and define the clinical sites most likely to assure participation and representativeness. This is where AI can be “AI for Good” and where technology does not introduce a bias but assures that biases don’t enter the process, the ultimate design, or the operational processes around the clinical trial.

What role does ConcertAI play in reducing the burden on healthcare providers and optimizing site selection in clinical trials?

We integrate the work burden into all aspects of our clinical trial solutions. First, there is a burden on the patient. This can be where the site is located, the number of visits required for a study versus the standard of care, or the clinical intensity of a study versus the standard of care, as in the case of additional biopsies. These things can determine whether the patient—or the patient in consultation with their provider—can afford to participate or tolerate and complete participation.

There is also a burden on the provider. If we can automate the identification of patients for clinical trial eligibility, minimize false positives that create work, and provide what we call “AI leverage” to the work of the Clinical Research Associated, Study Nurses, and Physicians, then the burden is lowered. The same is true of our AI Automation Solution, which allows the research team to avoid doing manual data entry—typically 2 to 4 hours at the end of the day, and often completed at home. Early on we looked at the data in the EMR—digital—being manually entered into a portal for the sponsor’s EDC. So digital data is being read and then rekeyed to become digital data again! Here, too, we are using our multi-tuned large language models—this was a real focus of the NVIDIA partnership from the beginning. We are at 55% full automation today, with a very fast path to over 80% in the coming few months. As these elements come together, we’ll get the staff time down to 10% of legacy requirements and make these studies more accessible to more patients.

Precision medicine is a key area where AI is making significant strides. How does ConcertAI’s technology contribute to more precise and personalized cancer treatments?

We’ve not discussed this too much since last year. In December 2023, we assumed responsibility for the American Society of Clinical Oncology’s (ASCO) CancerLinQ program. It is the world’s largest intelligent health network, comprising academic centers, regional hospital systems and community providers. A key part of this network is implementing the ASCO Certified® quality and clinical pathway solutions. Since CancerLinQ is a ConcertAI initiative, we have been growing the network, automating precision oncology pathways, creating new digital twin approaches for augmenting treatment selection for the providers, identifying and messaging critical diagnostic tests that could inform treatment decisions, and doing the same for newly approved medicines that represent another or better treatment alternative. All of this is underpinned by our CARAai™ architecture, again a set of vision LLM and tuned oncology LLMs done in collaboration with NVIDIA. It’s amazing to see the progress being made, and we’re excited about what we’ll be publishing and presenting at next year’s ASCO 2025.

How do you see AI imaging solutions benefiting fields like oncology and radiology, especially as these fields face clinician shortages?

Great question! It is true that both the number of new oncologists and radiologists entering the field is less than the number retiring. However, patient demand is ever-increasing. So, it is the ideal area for providing AI SaaS solutions that support physician and allied care professionals in both workflow optimization and clinical decision augmentation. Radiologists and oncologists will both cite the importance of these new intelligent solutions coming into their fields specifically. Imaging is a wonderful area for AI, and its performance is exceptional. Non-inferiority studies reflect that AI models can be close to or comparable to expert humans in narrow areas. Orchestrated workflows can bring this all together. The same is true in oncology, where we are bringing together molecular test results with immune response data, predictive algorithms for resistance and other elements that will all inform the treatment decision and enable response monitoring. I’ve been in the field for years and on different sides of new innovations—what we can do now is well beyond anything we were ever able to do before, and the pace of change is amazing.

As an experienced leader in healthcare technology, what advice would you offer to new companies looking to make a meaningful impact in healthcare through AI?

You can’t be an AI company without access to data at scale. Data is the substrate for building training and monitoring models. Also, building AI solutions is a team sport. You need domain knowledge at an exceptional depth matched with a new generation of AI model development capabilities that recognizes the behaviors of different classes of AI solutions and can bring them to bear against narrow objectives, specifically tuned for human or above performance. Then, these approaches can be orchestrated in various ways to represent a new system for operating—that is where the changes occur, and the value gets delivered. Practice “AI Humility” as everything is amazing and exhibits things we couldn’t do even six months before. Yet, ‘amazing’ is not necessarily a product or a new way of working—it is just that, technology doing something new. It is the responsibility of the AI company to make it a new way of working and a new approach for delivering an astonishing level of value that was never accessible before. Finally, assume you need to demonstrate trust in business practices, AI models, and solution transparency. We’re still early in our societal journey, and we’re the ones who have to earn the trust to bring about the changes we’re capable of delivering.

Thank you for the great interview, readers who wish to learn more should visit ConcertAI.

[semiconductorsandelectronics]

Growth and Innovation in US Digital Twin Market

The digital twin market in the US is experiencing rapid growth, driven by the country's increasing digitalization and the widespread adoption of Internet of Things (IoT) technologies. As US businesses integrate IoT devices, they can gather real-time data to create accurate virtual models of physical assets, which enhances monitoring, simulation, and optimization across industries like manufacturing, healthcare, and smart cities. The push toward Industry 4.0 further accelerates this trend, emphasizing automation and data-driven decision-making. With significant investments from private companies and government initiatives, digital twin technologies are becoming essential tools for improving operational efficiency and fostering innovation in the US.

Increasing Digitalization and IoT Adoption

The increasing adoption of digitization and IoT technologies in the US is reshaping the digital twin market. As more businesses integrate IoT devices to gather real-time data, they can create accurate virtual models of physical assets, enhancing decision-making and operational efficiency. For instance, Boeing has leveraged digital twin technology to design, test, and maintain aircraft, reducing assembly time by 80%, software development by 50%, and maintenance costs. This trend promotes sustainability, with digital twins helping companies minimize waste and improve resource reuse. As IoT and digitization expand, the US digital twin market is evolving, transforming industries such as aerospace, manufacturing, and healthcare.

Government Initiatives and Funding

The US government is advancing digital twin technology through strategic initiatives, including a USD 285 million funding proposal in 2024 to establish a research institute under the CHIPS for America Program, focusing on semiconductors. This effort aims to improve design and manufacturing efficiency in the semiconductor industry. Additionally, the government supports smart manufacturing initiatives integrating digital twins to modernize practices and boost productivity. Collaborations with tech giants like Microsoft and IBM further drive innovation across industries, highlighting the government's commitment to leveraging digital twins for economic growth and technological progress.

Advancements in Healthcare Through Digital Twin Technology

Recent investments in digital twin technology are accelerating advancements in healthcare. The National Science Foundation (NSF), in collaboration with the National Institutes of Health (NIH) and the Food and Drug Administration (FDA), has awarded over USD 6 million to support seven research projects focused on leveraging digital twins for healthcare applications. These projects explore areas such as virtual clinical trials, artificial intelligence (AI)-driven decision-making, and personalized treatment strategies. By advancing technologies in areas like cardiovascular health and diabetes management, these initiatives aim to improve patient outcomes, enhance safety, and streamline clinical research and medical device development, ultimately transforming healthcare delivery across the US.

Strong Presence of Key Players

The US digital twin market is experiencing significant growth, largely driven by major players like General Electric (GE), IBM, Microsoft, PTC, ANSYS, and Amazon Web Services (AWS). These companies are at the forefront of innovation, continuously developing advanced digital twin technologies and forming key partnerships to expand their applications across various industries. Their contributions are helping sectors such as manufacturing, healthcare, and energy to improve efficiency, optimize operations, and drive innovation. The strong presence of these industry leaders not only boosts the US’s technological capabilities but also establishes the country as a global leader in digital twin solutions, driving economic growth and technological advancement across industries.

Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=225269522

Future Outlook of Digital Twin in the US

The US digital twin market is expected to grow significantly, driven by AI, 5G, and edge computing innovations. By 2030, sectors like aerospace, automotive, and renewable energy will see widespread adoption. The rise of smart cities and focus on decarbonization will also play a pivotal role. Startups and established players collaborate to develop scalable, cost-effective solutions, ensuring a competitive edge. With its strong technology ecosystem and innovation culture, the US is set to remain a leader in the global digital twin market.

[biopharmaceuticalindustry]

GenAI's Impact on Reshaping the Pharma Industry

Sameer Lal: In an interview, Sameer Lal discusses the impact of GenAI in reshaping the pharma industry. Exploring GenAI's transformative potential, emerging trends, and regulatory challenges, this discussion offers valuable insights for pharmaceutical executives navigating the evolving landscape of AI in drug development and commercialisation. It also sheds light on the potential impact of GenAI adoption on the pharma workforce. John Ward: The integration of Generative AI (GenAI) technologies in the pharmaceutical industry represents a significant paradigm shift, promising to enhance drug discovery, streamline manufacturing processes, and optimise knowledge management. We discuss the methodology of implementing GenAI tools, such as automated document generation, AI-driven simulation models for clinical trials, and adaptive learning systems for workforce training. Andree Bates: Generative AI (GenAI) holds tremendous promise for automating drug design, speeding up clinical trials with synthetic data and digital twins, automating many aspects of regulatory and medical affairs and personalising sales and marketing. Nevertheless, fully realising these advancements while managing associated risks demands meticulous planning from both industry and regulators.

Read more: https://www.pharmafocusasia.com/information-technology/impact-on-reshaping-the-pharma-industry

[marketanalysisdata]

Clinical Trial Supplies Industry – Emerging Players May Yields New Opportunities Till 2030

The global clinical trial supplies market was valued at USD 2.58 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. Key drivers of this growth include the globalization of clinical trials and the increasing number of biologic and biosimilar drugs in development. Biologic and biosimilar drugs are particularly complex and often temperature-sensitive, necessitating specialized handling and storage throughout the supply chain. The rapid adoption of advanced supply chain management systems, aimed at increasing operational efficiency and managing the high R&D expenditure of biopharmaceutical companies, is expected to further drive growth in this market. As clinical trial supplies represent a substantial portion of R&D costs, streamlining supply chain processes has become a priority for biopharmaceutical firms.

Most clinical trials today are conducted in developing regions, where cost savings and access to diverse patient populations can be achieved. Rising costs associated with clinical trials, alongside the complexities of patient recruitment, have led many biopharmaceutical companies to outsource trials to areas such as Asia Pacific, Latin America, Central & Eastern Europe, and the Middle East. These regions offer significant advantages, including access to patients with varied disease profiles, which supports trials for rare diseases. Certain countries, such as China and Singapore, actively support biomedical research, allocating government funds to attract biopharmaceutical companies. Latin America, on the other hand, offers reduced language barriers, which simplify the process of obtaining informed consent, expediting the trial process.

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Supplies Market

Investments in advanced supply chain management software by clinical trial supply providers have been on the rise. Increasing trial complexity, as well as heightened competition, are pushing the industry to adopt new technologies that enhance supply chain planning and inventory management. For instance, inventory management software and digital twin technology are used in pharmaceutical manufacturing to create simulated environments that predict biological responses, helping speed up the drug development process by reducing reliance on physical samples and maximizing laboratory testing accuracy.

Clinical Phase Segmentation Insights:

Phase III clinical trials held the largest share of the clinical trial supplies market in 2023, accounting for 52.75% of total global revenue. Phase III trials are the most complex stage of clinical research, as they require larger sample sizes and more rigorous study designs to determine optimal dosing levels. Additionally, Phase III trials have the highest failure rates, often due to non-compliance with safety and efficacy standards, leading to significant financial and human costs. These challenges underscore the need for efficient clinical trial supply chains and logistics, which is expected to positively impact market growth in the coming years.

Phase I clinical trials are projected to exhibit the fastest CAGR of 7.0% over the forecast period. These trials, which involve a smaller patient population but require high capital investment, are increasingly being outsourced due to the associated cost benefits. The rise in outsourced Phase I clinical trials and the continued globalization of clinical trials are key factors expected to drive demand for clinical trial supplies at this early stage of drug development.

Order a free sample PDF of the Clinical Trial Supplies Market Intelligence Study, published by Grand View Research.

[marketstudyreport]

Clinical Trial Supplies Market Status, Growth Opportunities And Competitive Landscape till 2030

The global clinical trial supplies market was valued at USD 2.58 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 6.5% from 2024 to 2030. Key drivers of this growth include the globalization of clinical trials and the increasing number of biologic and biosimilar drugs in development. Biologic and biosimilar drugs are particularly complex and often temperature-sensitive, necessitating specialized handling and storage throughout the supply chain. The rapid adoption of advanced supply chain management systems, aimed at increasing operational efficiency and managing the high R&D expenditure of biopharmaceutical companies, is expected to further drive growth in this market. As clinical trial supplies represent a substantial portion of R&D costs, streamlining supply chain processes has become a priority for biopharmaceutical firms.

Most clinical trials today are conducted in developing regions, where cost savings and access to diverse patient populations can be achieved. Rising costs associated with clinical trials, alongside the complexities of patient recruitment, have led many biopharmaceutical companies to outsource trials to areas such as Asia Pacific, Latin America, Central & Eastern Europe, and the Middle East. These regions offer significant advantages, including access to patients with varied disease profiles, which supports trials for rare diseases. Certain countries, such as China and Singapore, actively support biomedical research, allocating government funds to attract biopharmaceutical companies. Latin America, on the other hand, offers reduced language barriers, which simplify the process of obtaining informed consent, expediting the trial process.

Gather more insights about the market drivers, restrains and growth of the Clinical Trial Supplies Market

Investments in advanced supply chain management software by clinical trial supply providers have been on the rise. Increasing trial complexity, as well as heightened competition, are pushing the industry to adopt new technologies that enhance supply chain planning and inventory management. For instance, inventory management software and digital twin technology are used in pharmaceutical manufacturing to create simulated environments that predict biological responses, helping speed up the drug development process by reducing reliance on physical samples and maximizing laboratory testing accuracy.

Clinical Phase Segmentation Insights:

Phase III clinical trials held the largest share of the clinical trial supplies market in 2023, accounting for 52.75% of total global revenue. Phase III trials are the most complex stage of clinical research, as they require larger sample sizes and more rigorous study designs to determine optimal dosing levels. Additionally, Phase III trials have the highest failure rates, often due to non-compliance with safety and efficacy standards, leading to significant financial and human costs. These challenges underscore the need for efficient clinical trial supply chains and logistics, which is expected to positively impact market growth in the coming years.

Phase I clinical trials are projected to exhibit the fastest CAGR of 7.0% over the forecast period. These trials, which involve a smaller patient population but require high capital investment, are increasingly being outsourced due to the associated cost benefits. The rise in outsourced Phase I clinical trials and the continued globalization of clinical trials are key factors expected to drive demand for clinical trial supplies at this early stage of drug development.

Order a free sample PDF of the Clinical Trial Supplies Market Intelligence Study, published by Grand View Research.

[trendtrackershq]

Strategic Analysis of the Digital Twins in Healthcare Market

Market Growth and Trends

The Digital Twins in Healthcare market is experiencing significant growth, driven by advancements in artificial intelligence (AI), machine learning, and data analytics. The rising demand for personalized medicine and the increasing focus on predictive healthcare are major factors contributing to the market's expansion.

Download a FREE Sample: https://www.nextmsc.com/digital-twins-in-healthcare-market/request-sample

Key Applications

Patient Monitoring and Care: Digital twins allow for continuous monitoring of patients, enabling healthcare providers to detect abnormalities early and adjust treatment plans in real-time. This technology is particularly beneficial for managing chronic diseases, where continuous data collection and analysis are crucial.

Surgical Planning and Simulation: Surgeons can use digital twins to simulate and practice complex procedures, reducing risks and improving outcomes. By creating a virtual model of a patient's anatomy, surgeons can plan and execute surgeries with greater precision.

Drug Development and Testing: Pharmaceutical companies are leveraging digital twins to simulate drug interactions and predict outcomes, speeding up the drug development process and reducing costs associated with clinical trials.

Hospital Management: Digital twins are also being used to optimize hospital operations, from managing patient flow to maintaining medical equipment. This results in improved efficiency and reduced operational costs.

Access Full Report: https://www.nextmsc.com/report/digital-twins-in-healthcare-market

Conclusion

The Digital Twins in Healthcare market is poised to revolutionize the medical field by enabling more personalized, predictive, and efficient care. As technology continues to advance, the adoption of digital twins will likely become a standard practice in healthcare, leading to improved patient outcomes and more efficient healthcare systems.

[priyarao-01]

AI and Data Science: Optimizing Clinical Trials and Research

The integration of artificial intelligence (AI) and data science into clinical trials represents an important shift in the healthcare industry. These technologies play a crucial role in optimizing various stages of clinical trials, from patient recruitment to data analysis. According to the National Institutes of Health, introducing a new medicine to the market costs over $1 billion. It can take up to 14 years, with a 12-month clinical trial potentially generating up to 3 million data points. By focusing on enhancing clinical trial efficiency and accuracy, AI and data science are changing how medical research is conducted and improving outcomes.

Improving Trials & Research with Artificial Intelligence

Traditional methods of patient recruitment are often slow and inefficient, relying on manual processes that can miss suitable candidates. AI, on the other hand, can analyze large volumes of data from electronic health records (EHRs), social media, and other sources to identify potential participants more quickly and accurately. For instance, AI tools have improved patient recruitment by mining vast datasets to identify suitable candidates, streamlining the process and ensuring that clinical trials are populated with the right participants. This not only saves time but also reduces costs and enhances the success rates of clinical trials, according to the US Food and Drug Administration (FDA).

What Role Does AI Play in Analyzing Real-World Data?

AI has been employed to analyze real-world data from EHRs and medical claims, aiding in the identification of patient cohorts and clinical trial design. This approach enables researchers to create more accurate and representative samples, thereby increasing the validity and reliability of trial outcomes. The FDA noted that predictive modeling in clinical trials, where AI forecasts patient outcomes based on baseline characteristics, enhances participant selection and ensures that the trials are more tailored and effective.

Are AI-Driven Chatbots Transforming Medical Research?

AI-driven chatbots are another innovative application in medical research as they provide accurate information about cancer treatments and clinical trials, improving patient engagement and education. Although they require further refinement to ensure accuracy, their potential to support clinical research and patient care is immense, according to the NCI. The future of AI and data science in clinical research looks promising, with several trends shaping the landscape. The National Institutes of Health’s (NIH) Bridge2AI program, for example, aims to generate AI-ready data and best practices for machine learning analysis, addressing complex biomedical challenges. This program exemplifies the growing trend toward collaborative and interdisciplinary approaches in healthcare research.

Role of AI in Enhancing Real-World Data Analysis

AI’s application in real-world data analysis is another area of significant impact. By analyzing EHRs and medical claims, AI helps identify patient cohorts and design more effective clinical trials. This use of real-world data ensures that clinical trials are based on comprehensive and accurate patient information, leading to more reliable results. The NIH’s Bridge2AI program is a testament to the growing importance of AI in healthcare research, generating AI-ready data and best practices for machine learning analysis.

Additionally, AI’s potential in clinical research is vast, with applications ranging from natural language processing (NLP) to machine learning (ML) to generative AI. These technologies analyze medical literature, extract relevant information, and generate new insights that drive innovation in healthcare. For example, the National Cancer Institute (NCI) funds numerous projects that integrate AI to enhance decision-making and care delivery. AI technologies, such as computer-aided detection and digital twins, are being refined to improve cancer screening and treatment planning. Digital twins, which are computerized ‘twins’ of patients, model medical interventions and provide biofeedback before actual treatment, enhancing the precision and efficacy of interventions, as per the FDA.

Machine Learning (ML) involves algorithms that improve through experience, enabling the identification of patterns in data that can predict drug efficacy. Besides, it helps analyze complex datasets to find correlations that might not be evident through traditional methods. In this regard, Dr. Reddy’s Laboratories’ subsidiary Aurigene introduced an AI and ML-assisted drug discovery platform in April 2024 that uses an iterative ML process for logical and effective chemical design, accelerating projects from hit identification to candidate nomination.

In June 2024, IQVIA launched the OneHome Clinical Trial Technology Platform, utilizing AI and data science to optimize various aspects of clinical trials, particularly in drug discovery. This Gen AI platform is designed to support decentralized trials, enhancing processes such as patient recruitment, real-time data monitoring, and trial management. By integrating with electronic health records (EHRs) and other data sources, OneHome can more efficiently identify eligible participants, potentially reducing recruitment times and improving trial outcomes. The platform’s AI-driven analytics enable continuous monitoring of patient data, allowing for timely interventions and adaptive trial designs, which may lead to more streamlined and accurate clinical trials. This approach demonstrates the increasing role of advanced technologies in enhancing the efficiency and effectiveness of clinical trials.

Case Study: AI in Oncology Clinical Trials

In a recent clinical trial focusing on oncology, AI was utilized to streamline patient recruitment and data analysis. The trial aimed to evaluate the effectiveness of a new immunotherapy treatment for lung cancer. Traditional recruitment methods have been challenging due to the specific patient criteria required. By implementing AI-driven tools to analyze EHRs, the research team identified eligible participants more efficiently.

This approach reduced recruitment time by 30%, enabling the trial to commence sooner than anticipated. Throughout the trial, AI algorithms continuously monitored patient data, providing real-time insights and identifying any anomalies. This proactive monitoring ensured prompt intervention when necessary, thereby maintaining the integrity of the trial and enhancing patient safety. The use of AI also facilitated adaptive trial design, allowing modifications based on interim results, which improved the overall efficacy of the study.

The Importance of Data Science in Clinical Trials

Data science plays a crucial role in managing and analyzing clinical trial data. Its applications in healthcare include clinical trial data management, statistical analysis, and predictive modeling. Handling large and complex datasets allows researchers to draw meaningful insights that drive the development of new treatments and therapies.

For example, data science tools facilitate the��visualization of healthcare data, making it easier for researchers to interpret complex results and make informed decisions. Real-time monitoring of clinical data ensures that trials are conducted efficiently, with issues identified and addressed promptly. Predictive modeling is particularly beneficial in clinical trials are it can forecast patient responses to treatments, allowing for more personalized and effective therapeutic approaches. This capability is especially valuable in designing adaptive clinical trials, which can modify protocols based on interim results, thus improving trial efficiency and patient outcomes, according to the FDA.

Final Thoughts: The Future Impact of AI and Data Science on Clinical Trials

In summary, AI and data science are redefining research and clinical trials by enhancing efficiency, accuracy, and patient outcomes. Their applications range from improving patient recruitment and data management to advancing predictive modeling and personalized medicine. As these technologies continue to evolve, they promise to bring about significant breakthroughs in healthcare, paving the way for a more effective and efficient medical research landscape.

[jobtendr]

(44) PhD, Postdoc and Academic Positions at Wageningen University & Research in Netherlands

Wageningen University & Research in Netherlands invites application for vacant (44) PhD, Postdoc and Academic Positions Wageningen University & Research in Netherlands invites application for vacant PhD, Postdoc and Academic Positions , a public university in Wageningen, The Netherlands. Men’s Football Coach/ Voetbaltrainer herenDo you have a passion for sports and in particular for Football? Would you like to teach others something and are you able to enthuse a group of fanatical students? Then we at S… Non-academic Natural sciences Support staff MBO PhD in Plant-based alternatives to milk fat globule membranes – the role of polar lipidsAre you interested in understanding the chemistry behind plant-based ingredients? Do you want to contribute to the transition to plant-based foods? Do you have a strong… Academic Food PHD Academic PhD position – Quantifying the dependence of natural ecosystems on pollinatorsDo you have a passion for plants and pollinators? Are you concerned about the consequences of pollinator decline for plant biodiversity? Do you want to understand how plants and… Academic Natural sciences PHD Academic PhD position – Optimizing nutrient budgets for zero water pollution in EuropeAre you passionate about nutrient pollution issues in Europe? Do you want to pursue an interdisciplinary PhD research project in which you will optimize nutrient budgets fo… Academic Agriculture PHD Academic SecretaryAs the secretary of our business unit, you support and relieve our management team in secretarial and administrative matters. Since much of the communication here is in Dutch, f… Non-academic Agriculture Support staff MBO Team leader Applied Ecology in agrosystemsWould you like to contribute to the mission of WUR, particularly that of Agrosystems Research, by leading a team of professionals and managing larger, complex research … Non-academic Agriculture Management Graduate Education SupportWe are looking for an education support colleague for the department of Food Quality and Design (FQD) at Wageningen University. Yo… Academic Food Professors/lecturers Academic Executive assistantWould you like to work as an executive secretary in an environment with friendly colleagues and a good work-life balance? Are you organizationally strong and enjoy taking work o… Non-academic Behavior and society Support staff MBO+ PhD on the functionality of milk fat globule membrane ingredients: influence by composition and processed-induced variationThe Food Quality and Design group of Wageningen University and Research (FQD, WUR) offers a PhD position on milk fat globule membrane functionality to a highly motivate… Academic Food PHD Academic Management- en Office-AssistantAre you a proactive management and office assistant, and an administrative allrounder? Are you fluent in Dutch and English? Do you maintain an overview and serve as a communi… Non-academic Agriculture Support staff Editorial assistant for the Statutory Research Task teamAre you someone who likes to keep everything running smoothly and has a passion for nature and the environment? Do you get excited about the careful preparation, execution, a… Non-academic Agriculture Support staff MBO PhD position in spatiotemporal diversity of phagesDo you want to pursue a PhD in computational biology? Are you interested in the genome diversity of bacteriophages across space and time? Do you want to combine bioinfo… Academic Agriculture PHD Academic PhD student – Sweet spot: spot-on usage of non-nutritive sweetenersAre you looking for a position as a PhD student? Do you want to set up and run a clinical trial to discover how non-nutritive sweeteners affect physiology, metabolism a… Academic Food PHD Academic Post-doc: A digital twin for marine fish trackingDo you want to study fish movement ecology using large telemetry databases? Then we might have a position for you!The Academic Natural sciences Postdoc Academic Researcher European forest resourcesDo you want to become part of one of the leading forest modelling groups in Europe? Then this is a great opportunity to join our team and help us to further develop our for… Academic Agriculture Research / Innovation Graduate Assistant (HBO) Researcher Advanced Cultivation Systems Greenhouse HorticultureAs assistant researcher advanced cultivation systems you participate at our location in Bleiswijk in research projects on optimal conditions for growth, development and production … Academic Agriculture Research / Innovation HBO Office ManagerDo you want to work in an environment with great colleagues, a good work-life balance, and where independence is valued? Are you organizationally strong and enjoy … Non-academic Food Support staff HBO Researcher Advanced Cultivation Systems Greenhouse HorticultureAs researcher advanced cultivation systems you participate at our locations in Wageningen and Bleiswijk in research projects on optimal conditions for growth, development and produ… Academic Agriculture Research / Innovation HBO Researcher Water QualityAre you an enthusiastic … Academic Agriculture Research / Innovation Academic Technician for research and educationDo you have experience in technical support within education and research, and do you feel at home in a multicultural international environment? Are you interested in soil an… Academic Natural sciences Research / Innovation HBO Head of the department Epidemiology, Bioinformatics and Animal StudiesAre you looking for a job where you can continue to grow as a supervisor? A job where you help prevent the spread of animal diseases and promote good animal health. At … Non-academic Agriculture Management Academic Laboratory Technician / Assistant Researcher in ShellfishAre you passionate about marine ecology and experimental research? Do you want to work at a leading research institute? Do you hold a Bachelor&… Academic Natural sciences Research / Innovation HBO PhD Position: AI-powered identification of anomalies and manipulation in electricity marketsHave you ever wondered how electricity markets can be manipulated and how to effectively identify anomalies and market abuse from electricity markets data? Are you interested… Academic Engineering PHD Academic PhD position – Behaviour and environmental fate of ionizable pollutantsAre you a talented environmental scientist, soil scientist, biologist, ecologist or an ecotoxicologist with demonstrated experience in conducting experimental research? Do you l… Academic Agriculture PHD Academic Functional Application Support Officer Sr.Are you passionate about HR applications that enable easy service delivery for all stakeholders, support the goal of data-driven management and continuous improvement, … Non-academic Engineering ICT HBO Lecturer Health and SocietyThe lecturer position will mainly contribute to the HSO teaching portfolio. We are looking for someone who can support education (courses and thesis and internship supervision). Th… Academic Behavior and society Professors/lecturers Graduate PhD Researcher: Exploring Water Scarcity Governance Responses Across Different SocietiesAre you passionate about researching social science dimensions of climate change and water scarcity? Do you want to explore how diverse communities and governance actor… Academic Behavior and society PHD Academic Junior Lecturer in Geo-Information Science / Remote SensingAre you an enthusiastic and hardworking person with knowledge of geo-information, remote sensing and its applications? Are you enthusiastic about academic teaching, lec… Academic Natural sciences Professors/lecturers Academic Researcher Land use and climate (LULUCF)Are you a broadly interested researcher with a university degree? Are you fascinated by sustainability issues and do you have experience and affinity with researching t… Academic Natural sciences Research / Innovation Academic Senior Lecturer in Geo-Information Science / Remote SensingAre you an enthusiastic and hardworking person with knowledge of geo-information, remote sensing and its applications? Are you enthusiastic about academic teaching, lec… Academic Natural sciences Professors/lecturers Graduate Electrical engineerAre you the electrical engineer who will keep our installations in top shape?In the high-tech greenhouses of our experimental farm in Bleiswij… Non-academic Agriculture Technical / Laboratory MBO+ Performance MarketerAs a Performance Marketer at Wageningen University & Research (WUR), you will have the opportunity to elevate our advertising campaigns to the next level. Your mission is clear… Non-academic search_scientificfield_language__and_culture Marketing / Sales / Communication HBO Assistant or Associate Professor (Tenure Track): Farming Systems AnalysisDo you have a strong background in quantitative analyses of agricultural systems? Are you passionate about participatory approaches and eager to make a difference in Af… Academic Agriculture Professors/lecturers Graduate Phd in Diet, faecal microbiota and chemotherapy in patients with colon cancerThe impact of nutrition on cancer treatment fascinates us. Are you interested in working with us on an exciting project focussing on the intersection between nutrition,… Academic Food PHD Academic PhD in Ex situ and in situ quantification of structure-functional relationships in texturized novel protein sourcesAre you interested in developing cutting-edge ex situ and in situ NMR/MRI measurement techniques for characterizing structure and texture formation in novel protein sou… Academic Food PHD Academic PhD researcher – Empowering optimal design for greater resilience of the electricity gridWe are looking for an enthusiastic PhD researcher to conduct cutting-edge research at the interface of resilience and the electricity grid, combining socioeconomic, spat… Academic Economics PHD Academic PhD in Microbiota and CRC treatmentWe are looking for an ambitious PhD candidate with a great interest in the ecology of intestinal microbes for a project that is on  the intersection between microb… Academic Natural sciences PHD Academic Research Computers System AdministratorWe are looking for a Research Computing System Administrator to contribute to the research and teaching mission of the Experimental Zoology group (EZO). Within the technicians&rsqu… Non-academic Natural sciences Support staff Academic Assistant/associate professor in human studies, encompassing thorough phenotyping and molecular investigations within human dietary intervention studiesWe have an exciting opportunity for an Assistant/Associate Professorship in Molecular Nutrition and Metabolism within the Nutrition, Metabolism, and Genomics group at W… Academic Food Professors/lecturers Graduate Assistant/associate professor in nutritional regulation of molecular pathways in cellular and animal modelsWe have an exciting opportunity for an Assistant/Associate Professorship in Molecular Nutrition and Metabolism within the Nutrition, Metabolism, and Genomics group at W… Academic Food Professors/lecturers Graduate Lecturer position in Animal BehaviourThe chair group Behavioural Ecology at Wageningen University is offering a position as Lecturer in Animal Behaviour. As a lecturer, you will take … Academic Natural sciences Professors/lecturers Graduate PhD Researcher in land change monitoring for tree diversityAre you a motivated and curious individual with a strong interest in remote sensing, plant ecology, land change monitoring, vegetation dynamics and tree diversity? Do you h… Academic Natural sciences PHD Academic SecretaryAs secretary you will be working at the secretariat of the Microbiology chair group. The secretariat currently consists of two secretaries, a financial officer and oper… Non-academic Natural sciences Support staff MBO Postdoctoral researcher in ethnographies of marine restoration and global China in Southeast AsiaThe Environmental Policy Group at Wageningen University and Research is looking for an emerging scholar in the field of anthropology/geography, marine restoration, and geop… Academic Behavior and society Postdoc Graduate Read the full article

[uptothetrendblogs]

Digital Twin in Healthcare Market: Revolutionizing the Industry

Digital Twin technology is emerging as a revolutionary force in the healthcare industry, offering unprecedented opportunities for enhancing patient care, optimizing operations, and driving innovation. A Digital Twin is a virtual replica of a physical entity, such as a patient, medical device, or even a hospital system, that uses real-time data and advanced simulation techniques to mirror its real-world counterpart. This cutting-edge technology is poised to transform healthcare by enabling personalized medicine, predictive analytics, and efficient management of healthcare resources.

Request To Download Sample of This Strategic Report  -  https://univdatos.com/report/digital-twin-in-healthcare-market/

Latest Developments

Personalized Medicine and Patient Care: The application of Digital Twin technology in personalized medicine has gained significant traction. By creating a virtual model of a patient, healthcare providers can simulate different treatment scenarios and predict their outcomes. This approach allows for tailoring medical interventions to individual patient needs, improving efficacy, and reducing side effects. For instance, in 2023, researchers at the University of California, San Francisco, developed a Digital Twin model to predict the progression of chronic diseases, such as diabetes and cardiovascular conditions, enabling early intervention and better management.

Advanced Surgical Planning: Digital Twins are increasingly used in surgical planning and training. Surgeons can practice complex procedures on virtual models before operating on real patients, enhancing precision and reducing risks. In recent news, Mayo

Clinic collaborated with a leading tech company to create detailed Digital Twins of patients' organs, which are used to plan and rehearse surgeries. This collaboration has led to a significant decrease in surgical errors and improved patient outcomes.

Hospital Management and Operations: The COVID-19 pandemic highlighted the need for efficient hospital management and resource allocation. Digital Twins can simulate hospital operations, predicting patient influx and optimizing the use of medical resources. In a recent development, Cleveland Clinic implemented a Digital Twin of their entire hospital system to manage patient flow and resource distribution during the pandemic. This system proved instrumental in reducing wait times and improving the overall efficiency of hospital operations.

Medical Device Development and Testing: Medical device manufacturers are leveraging Digital Twins to accelerate the development and testing of new products. By creating virtual prototypes, companies can conduct extensive testing in a simulated environment, reducing the need for physical trials and speeding up time-to-market. GE Healthcare, for example, has been at the forefront of using Digital Twins to optimize the design and functionality of their imaging devices, ensuring higher reliability and performance.

Market Analysis

The global Digital Twin in Healthcare market is experiencing robust growth, driven by technological advancements, increasing adoption of IoT and AI in healthcare, and the growing need for personalized medicine. According to a recent report by MarketsandMarkets, the market is expected to grow from USD 1.5 billion in 2021 to USD 5.1 billion by 2026, at a CAGR of 27.2%.

Several factors contribute to this growth:

Technological Advancements: The integration of IoT devices, AI, and machine learning algorithms with Digital Twin technology is enhancing its capabilities. Advanced sensors and wearable devices collect real-time patient data, which is then processed by AI algorithms to create accurate and dynamic Digital Twins. This synergy between technologies is driving the adoption of Digital Twins in healthcare.

Increasing Investment: Significant investments from both public and private sectors are fueling the growth of the Digital Twin market. Governments and healthcare organizations are recognizing the potential of this technology to improve patient care and reduce costs. In 2023, the European Commission launched a major initiative to fund Digital Twin projects in healthcare, aiming to foster innovation and adoption across the continent.

Growing Demand for Personalized Medicine: The shift towards personalized medicine is a major driver for the adoption of Digital Twins. Patients and healthcare providers are increasingly seeking treatments tailored to individual genetic, environmental, and lifestyle factors. Digital Twins enable precise modeling of these factors, facilitating personalized treatment plans and improving patient outcomes.

Regulatory Support: Regulatory bodies are also supporting the use of Digital Twins in healthcare. The FDA, for example, has introduced guidelines for the use of Digital Twins in medical device testing and approval processes. This regulatory support is expected to encourage more healthcare organizations to adopt the technology.

𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐒𝐭𝐫𝐚𝐭𝐞𝐠𝐢𝐜 𝐒𝐚𝐦𝐩𝐥𝐞 𝐏𝐃𝐅 𝐇𝐞𝐫𝐞-  https://univdatos.com/report/digital-twin-in-healthcare-market/get-a-free-sample-form.php?product_id=58944

Challenges and Future Prospects

Despite its promising potential, the Digital Twin in Healthcare market faces several challenges. Data privacy and security concerns are paramount, as the technology relies heavily on sensitive patient data. Ensuring the accuracy and reliability of Digital Twins is also crucial, as inaccuracies can lead to suboptimal treatment outcomes.

Looking ahead, the future of Digital Twins in healthcare is bright. Continued advancements in AI, machine learning, and data analytics will enhance the capabilities and applications of Digital Twins. Collaboration between technology companies, healthcare providers, and regulatory bodies will be essential to address challenges and drive widespread adoption.

In conclusion, Digital Twin technology is set to revolutionize the healthcare industry, offering immense potential for improving patient care, optimizing operations, and driving innovation. As the technology continues to evolve and mature, its impact on healthcare is expected to grow, ushering in a new era of precision medicine and efficient healthcare management.

Contact Us: UnivDatos Market Insights Email - contact@univdatos.com  Contact Number - +1 9782263411 Website - www.univdatos.com

[ateamsoftsolutions01]

How Australian Tech Startups Are Revolutionizing Industries in 2024?

In 2024, Australian tech startups are making a significant impact across various industries, driving innovation and disrupting traditional business models. Here’s how these dynamic startups are revolutionizing industries and setting new standards for success.

1. Healthcare Innovation

Australian tech startups are transforming healthcare with cutting-edge technologies. Companies like HealthMatch and Eucalyptus are leveraging AI and telemedicine to improve patient care and access. HealthMatch’s AI-powered platform matches patients with clinical trials, accelerating medical research, while Eucalyptus provides digital healthcare services, making medical consultations and treatments more accessible.

2. Fintech Advancements

The fintech sector is booming with Australian startups leading the charge. Firms like Afterpay and Airwallex are revolutionizing payment systems and global transactions. Afterpay’s buy-now-pay-later model has redefined consumer credit, while Airwallex offers seamless cross-border payment solutions for businesses, enhancing financial efficiency and reducing costs.

3. Agri-Tech Transformation

Agri-tech startups are reshaping the agricultural landscape. Companies such as AgriDigital and The Yield are utilizing blockchain and IoT technologies to enhance supply chain transparency and optimize farming practices. AgriDigital’s blockchain platform ensures secure and transparent agricultural transactions, while The Yield’s IoT solutions provide real-time data to improve crop management and yield predictions.

4. Education Technology

Edtech startups in Australia are revolutionizing education by making learning more interactive and accessible. Organizations like Cluey Learning and OpenLearning offer personalized online tutoring and collaborative learning platforms. These startups are enhancing educational experiences and ensuring that quality education is accessible to students regardless of their location.

5. Sustainable Energy Solutions

The push for sustainability is driving innovation in the energy sector. Startups like Relectrify and Redback Technologies are developing advanced energy storage and management systems. These innovations support the integration of renewable energy sources, reduce reliance on fossil fuels, and promote sustainable living.

6. Smart Cities Development

Australian startups are also contributing to the development of smart cities. Companies like Urban.io and Lendlease Digital are creating smart infrastructure solutions that improve urban living. Urban.io’s sensor technology enables efficient city management, while Lendlease Digital’s digital twin technology helps in planning and maintaining urban infrastructure.

7. Retail and E-commerce Evolution

Retail and e-commerce are being transformed by tech startups. Brands like Koala and The Iconic are redefining customer experiences with innovative online shopping platforms and sustainable practices. Koala’s direct-to-consumer model and eco-friendly products have set new standards in the furniture industry, while The Iconic offers a seamless online shopping experience with a focus on sustainability.

In conclusion, Australian tech startups are revolutionizing various industries with innovative solutions and technologies. From healthcare to fintech, agri-tech, education, sustainable energy, smart cities, and retail, these startups are driving change and setting new benchmarks for success in 2024. Their contributions are not only advancing their respective industries but also enhancing the quality of life and promoting sustainable practices globally.

[unique-hospital]

INNOVATIONS TRANSFORMING CANCER TREATMENT: A LOOK AT CUTTING-EDGE TECHNOLOGIES

In the realm of cancer research, what once seemed like science fiction is now a tangible reality, all thanks to a myriad of technological advancements. These innovations are not just changing the way we perceive cancer treatment but are actively accelerating progress against this formidable disease. In this given blog Dr Ashish Gupta will help you understand some groundbreaking technologies that are reshaping the landscape of cancer care and ushering in a new era of hope and possibility.

Artificial Intelligence (AI)

Imagine having a digital twin- a virtual representation of yourself – crafted through sophisticated AI algorithms to help physicians tailor treatment plans with unparalleled precision. This futuristic concept is now within reach, thanks to the remarkable capabilities of artificial intelligence. By sifting through vast troves of data, AI can pinpoint patterns, aiding in cancer diagnosis, drug development, and personalized medicine. As per Dr Ashish Gupta, USA trained, American board-certified medical oncologist, Chief of Medical Oncology, Unique Hospital Cancer Centre, Dwarka India, whether it’s analyzing imaging data or predicting treatment outcomes, AI is poised to revolutionize every facet of cancer care, promising transformative advancements on the horizon.

Telehealth

In an age where connectivity reigns supreme, telehealth emerges as a beacon of hope, seamlessly bridging the gap between patients and cancer care providers. Especially crucial in the midst of a pandemic, telehealth has become instrumental in delivering cancer treatment and running clinical trials remotely. From remote health monitoring to video consultations, telehealth not only enhances accessibility but also ensures safety and convenience for patients and providers alike. However, the journey towards equitable telehealth access poses its own set of challenges, underscoring the ongoing need for research and innovation in this domain.

Cryo-Electron Microscopy (Cryo-EM)

Peer through the lens of cryo-electron microscopy, and you’ll behold a world of molecular intricacies previously unseen. With unprecedented resolution, Cryo-EM enables researchers to delve into the inner workings of molecules, unraveling the mysteries of cancer cell behavior and therapeutic interactions. Recent breakthroughs, such as visualizing drug interactions at the molecular level, exemplify the transformative potential of Cryo-EM in shaping future cancer treatments. As access to this cutting-edge technology expands, so too does our understanding of cancer biology, paving the way for targeted interventions and personalized therapies.

Infinium Assay

The secrets encoded within our genes, the Infinium Assay emerges as a powerful tool in deciphering the genetic underpinnings of cancer. By scrutinizing millions of genetic variations, this innovative assay sheds light on cancer risk, progression, and development. Initially met with skepticism, its journey from conception to widespread adoption showcases the tangible impact of taxpayer-funded innovation. From cancer research to population-wide genomic studies, the Infinium Assay holds immense promise in unraveling the genetic tapestry of cancer and beyond.

Robotic Surgery

Enter the realm of robotic surgery, where precision meets innovation to redefine the surgical landscape. With robotic arms wielding scalpel-like precision, complex cancer surgeries become minimally invasive affairs, offering patients faster recovery times and reduced postoperative discomfort. Beyond the allure of futuristic technology, robotic surgery epitomizes the marriage of precision and compassion, offering renewed hope to cancer patients worldwide.

Conclusion

As we stand at the precipice of a new era in cancer treatment, fueled by cutting-edge technologies, the future holds boundless promise and potential. From AI-driven personalized medicine to the precision of robotic surgery, each innovation represents a stepping stone towards a world where cancer is not just treatable but conquerable. By embracing and harnessing these transformative technologies, we embark on a journey towards a brighter, healthier tomorrow- one where cancer is no longer a formidable adversary but a conquerable challenge. If you are searching best cancer treatment, contact Dr Ashish Gupta, USA trained, American board-certified medical oncologist

[thehealthcareinsights-blog]

The Promise of Digital Twin Technology in Personalized Healthcare

Healthcare is the fastest and most highly evolving sector in today’s world, along with the birth of different technologies that are playing a vital role in the medical field in terms of solving new problems uniquely and helping professionals provide effective treatments. Digital twin technology is used in many fields and healthcare is one of its applications. DT is one among healthcare technologies and is an innovative approach that uses digital replicas of physical entities to predict various health-related issues. This has become a promising tool that can be used in transforming personalized healthcare. In this article, let us discuss in detail this technology and its prominent role in finding solutions to various health-related problems that are improving patient care. 

Defining Digital Twin Technology 

Digital twin technology is the process of creating or making virtual models that are replicas of real entities like human organs, systems, physiological acts, or even the entire organism. These virtual models can be used later for simulation, and analysis, and hence we can learn or understand the behavior of an individual in different conditions. This helps medical professionals or specialists to study the particular person in detail which in turn can be more effective and accurate in the diagnosis process. 

A DT on creating a virtual model can used to conduct surgeries and oversee the effects virtually that might occur on undergoing the real surgery on the patient’s body. This will help in preventing future harm and suffering from pain. All the virtual replicas are updated regularly with data from different sources like wearable health devices, genetic information, and electronic health records (EHRs) for maintaining accuracy. Thus, by integrating all this information doctors and find valuable insights into a patient’s health conditions and hence can provide personalized diagnoses.

Digital Twin Technology working in healthcare 

Digital twin technology mainly works by data integration from different healthcare resources. But it is done in three steps which include the creation of a blueprint, the construction of the first digital twin model, and the third is enhancing its capacity. The data that is integrated will contain the important elements of the patient like medical history, lifestyle, genetic makeup, physical behavior, and emotional factors. All these can be gathered using sensors or wearable medical devices. 

Later these digital twins are analyzed using advanced machine learning techniques that can identify and provide meaning or informative patterns, and prediction of future outcomes, and will also give suggestions that can be adopted in personalized treatment plans.

Benefits of Digital Twin Technology 

A DT technology can be used as the predicting analysis that showcases the results of your diagnosis without actually doing it on the human body. The process of regular and continuous monitoring of the updated real-time data through virtual twins doctors can detect the symptoms at the early stage and is an alert for professionals so that they can take precautionary measures for patients. With his proactive approach, many diseases can be prevented well before.

It is also a very useful approach to monitoring patients remotely as one need not visit physically to provide or get their health updates. This benefits chronic patients as it gives access to continous support and care by healthcare providers. The major use is to provide personalized care and precision medicines based on the individual’s unique character and genomic factor. Along with this analysis of various scenarios, one can get optimization in treatment depending on the outcome effects with this, doctors can adopt effective and better treatment strategies. Apart from all these DT is a powerful tool for learning drug effects, disease symptoms, and research areas for conducting clinical trials.

Conclusion

To conclude, along with its benefits in various areas of healthcare, certain challenges need to be encountered. The major difficulty is data privacy and security which comes with the major concern of misusing personal and detailed information of the patient. Accuracy may be also an issue as in some cases predictions may go wrong and may cause severe effects. With careful planning and implementation, digital twin technology has the potential to improve patient outcomes and transform the future of healthcare.

Visit More : https://thehealthcareinsights.com/the-promise-of-digital-twin-technology-in-personalized-healthcare/

[texploration]

Virtual Trials and Digital Twins in Clinical Trials

In the intricate and evolving landscape of healthcare, clinical trials stand as pivotal voyages of discovery, essential for unearthing new treatments and advancing medical knowledge. Yet, these crucial journeys are not without their challenges. Traditional clinical trials are often beleaguered by a myriad of obstacles – from the arduous task of enrolling enough suitable patients, to the…

[lanettcdmo]

Innovations Transforming Pharmaceutical Manufacturing

Introduction:

In the dynamic landscape of pharmaceutical manufacturing, constant innovation is the key to meeting the growing demand for safe and effective medications. As technology continues to advance, the industry is undergoing a transformative phase that brings about efficiency, quality improvements, and increased agility. This blog will explore some of the notable innovations shaping the future of pharmaceutical manufacturing.

Advanced Process Automation: Automation is revolutionizing pharmaceutical manufacturing by streamlining processes, reducing human error, and enhancing overall efficiency. From robotic process automation (RPA) in packaging to automated quality control systems, these technologies not only improve production speed but also ensure precision in drug formulation.

Digital Twins in Manufacturing: The concept of digital twins involves creating a virtual replica of the manufacturing process. This allows for real-time monitoring, analysis, and optimization of production. By integrating sensors and data analytics, pharmaceutical manufacturers can identify potential issues before they occur, minimizing downtime and improving overall quality.

Continuous Manufacturing: Traditional batch manufacturing is giving way to continuous manufacturing, a process that operates 24/7 without interruptions. This approach offers several advantages, including reduced production time, increased flexibility in adjusting formulations, and enhanced scalability. Continuous manufacturing aligns with the industry’s goals of improving efficiency and reducing waste.

3D Printing of Pharmaceuticals: 3D printing technology is making waves in pharmaceutical manufacturing by allowing the creation of personalized medications. This innovation enables the production of intricate drug structures that may have improved bioavailability and targeted drug delivery. The ability to customize drug formulations based on individual patient needs holds great promise for the future of medicine.

Blockchain for Supply Chain Transparency: Blockchain technology is being implemented to enhance transparency and traceability in the pharmaceutical supply chain. By providing an immutable and decentralized ledger, blockchain ensures the integrity of the entire manufacturing and distribution process. This not only helps in preventing counterfeit drugs but also facilitates quicker recalls and compliance with regulatory standards.

Artificial Intelligence (AI) in Drug Discovery: While not directly related to manufacturing, AI plays a crucial role in drug discovery, leading to the development of more effective medications. Machine learning algorithms analyze vast datasets to identify potential drug candidates and predict their success in clinical trials. This accelerates the drug development process and ultimately impacts manufacturing by bringing new products to market faster.

Conclusion:

The pharmaceutical contract manufacturing landscape is undergoing a significant transformation fueled by technological advancements. From automated processes to innovative approaches like continuous manufacturing and 3D printing, these changes are not only improving efficiency but also paving the way for personalized medicine. As the industry continues to embrace these innovations, the future holds exciting possibilities for safer, more effective, and accessible pharmaceuticals.